News / Taiwan / economic_daily
TaiHe Biotech IPO Opens for Subscription with Over 100% Potential Upside
Health Technology · Biotechnology · economic_daily · 2026-10-07
6467
TaiHe Biotech has launched its IPO subscription process with an offer price of NT$105.6, offering investors a potential gain of over 100% based on current market prices.
What Happened
IPO Subscription Details: TaiHe Biotech began its public subscription period on October 7, running through October 12, with the lottery scheduled for October 14. The company is set to list on October 20, with an offer price of NT$105.6, representing a significant discount compared to its recent OTC closing price of NT$220.57.
Drug Development Pipeline: The company's primary focus is its anti-thrombotic oral film drug, BEQIA (TAH3311). TaiHe is aggressively working toward securing FDA approval for this product by April 22, 2027.
Market Opportunity: The drug targets a massive global market valued at over $29.2 billion annually, or approximately NT$930 billion. By leveraging its proprietary oral film technology, TaiHe aims to capture a significant portion of this lucrative pharmaceutical segment.
Investment Outlook: While the IPO presents a substantial immediate profit opportunity, investors should remain cautious regarding the inherent volatility of biotech stocks post-listing. Monitoring the progress of regulatory approvals and the company’s operational milestones remains essential for long-term assessment.